1️⃣ FDA is turning animal-free science into filing policy
The FDA said on April 20 it had hit its first-year roadmap goals to reduce animal testing, after issuing new NAMs guidance, qualifying its first AI drug-development tool and launching a database on where alternatives are acceptable.
💡 Why it matters
This is moving from principle to review infrastructure. That changes preclinical cost, timelines and which platform bets look financeable.
☕ Coffee talk
The FDA is already qualifying AI tools and naming where animal alternatives fit. How long do tox budgets keep pretending nothing changed?
2️⃣ Lilly just paid for in vivo CAR-T access
Lilly agreed on April 20 to buy Kelonia for up to $7B, including $3.25B upfront, betting on a Phase 1 in vivo BCMA CAR-T platform that skips the usual ex vivo manufacturing loop.
💡 Why it matters
This is not just another oncology tuck-in. Big pharma is underwriting a new delivery model that aims to cut the cost and logistics burden that keeps cell therapy niche.
☕ Coffee talk
Two big Lilly moves into in vivo CAR-T in one quarter. How many teams still think ex vivo capacity is the long game?
3️⃣ Danaher just gave the cleanest tools readthrough in months
Danaher said on April 21 that Q1 revenue rose 3.5% to $6.0B and lifted the top end of full-year EPS guidance, citing strength in bioprocessing and better-than-expected life sciences demand.
💡 Why it matters
For the sector, this matters beyond one quarter. Suppliers are starting to sound like the post-destocking reset is giving way to a real operating cycle again.
☕ Coffee talk
Danaher just raised on bioprocessing. How many 2026 budgets were still built for another flat tools year?